The Federal Trade Commission (FTC) stated on Sept. 10 that it will not allow cannabis companies that produce CBD products to advertise that their products can “cure” certain medical conditions unless there is enough science to back up the claim.
According to Reuters, the top U.S. trade regulator said that it has already sent warning letters to three companies selling CBD-infused products. They can’t claim that products fight diseases unless there is verifiable, scientific evidence to support such a statement.
The three companies, whose names have been kept anonymous, claimed that CBD can treat more than two dozen conditions, including cancer, Alzheimer’s, multiple sclerosis, schizophrenia, epilepsy, diabetes, psoriasis and AIDS. The companies in question currently sell a variety of CBD products, including oils, tinctures, capsules, gummies and topical creams. Each company has 15 days to inform the FTC of how they plan to address and fix the issue. If they don’t successfully do so, the companies could receive more severe punishments in the future.
Often, when it comes to advertisements, CBD has been touted to fight ailments of all kinds. However, all cannabis companies must be careful that they do not state that any cannabis product is a “cure” that is not backed up with scientific evidence and studies. For example, one of the companies in question stated that their product “works like magic.” Another states that CBD has been clinically proven to treat Alzheimer’s and schizophrenia.
CBD is still new, and there are many studies in the works to determine the efficacy of its use for medical patients. Even the FDA has begun to organize efforts to find out how CBD helps patients. Although progress is slow, only time will tell how the U.S. government expects to move forward in this world of cannabis acceptance.